Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.

Several factors have contributed to Lilly's share price decline, including earnings misses and increased competition. For a ...